NASDAQ:DRRX DURECT (DRRX) Stock Forecast, Price & News $5.64 -0.11 (-1.91%) (As of 06/9/2023 ET) Add Compare Share Share Today's Range$5.60▼$6.0150-Day Range$4.05▼$7.0052-Week Range$3.16▼$9.70Volume185,317 shsAverage Volume146,469 shsMarket Capitalization$138.12 millionP/E RatioN/ADividend YieldN/APrice Target$36.25 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability DURECT MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside542.7% Upside$36.25 Price TargetShort InterestHealthy1.68% of Float Sold ShortDividend StrengthN/ASustainability-1.19Upright™ Environmental ScoreNews Sentiment0.76Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.82) to ($0.68) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.18 out of 5 starsMedical Sector291st out of 988 stocksPharmaceutical Preparations Industry129th out of 480 stocks 3.5 Analyst's Opinion Consensus RatingDURECT has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $36.25, DURECT has a forecasted upside of 542.7% from its current price of $5.64.Amount of Analyst CoverageDURECT has only been the subject of 2 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted1.68% of the float of DURECT has been sold short.Short Interest Ratio / Days to CoverDURECT has a short interest ratio ("days to cover") of 3.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in DURECT has recently increased by 11.48%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldDURECT does not currently pay a dividend.Dividend GrowthDURECT does not have a long track record of dividend growth. Previous Next 4.4 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreDURECT has received a 67.95% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for physiological diseases " and "Clinical research services for substance abuse disorders " products. See details.Environmental SustainabilityThe Environmental Impact score for DURECT is -1.19. Previous Next 2.6 News and Social Media Coverage News SentimentDURECT has a news sentiment score of 0.76. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for DURECT this week, compared to 2 articles on an average week.Search InterestOnly 2 people have searched for DRRX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows4 people have added DURECT to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, DURECT insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.50% of the stock of DURECT is held by insiders. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for DURECT are expected to grow in the coming year, from ($1.82) to ($0.68) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of DURECT is -3.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of DURECT is -3.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioDURECT has a P/B Ratio of 5.13. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About DURECT (NASDAQ:DRRX) StockDURECT Corp. focuses on advancing novel and potentially lifesaving investigational therapies derived from its Epigenetic Regulator Program. Its pipeline is called DUR-928, an endogenous sulfated oxysterol and an epigenetic regulator. The company was founded by James E. Brown and Felix Theeuwes on February 6, 1998 and is headquartered in Cupertino, CA.Read More Receive DRRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for DURECT and its competitors with MarketBeat's FREE daily newsletter. Email Address DRRX Stock News HeadlinesJune 7, 2023 | finance.yahoo.comDURECT Completes Enrollment in Phase 2b AHFIRM Trial of Larsucosterol in Alcohol-Associated HepatitisMay 28, 2023 | americanbankingnews.comDURECT (NASDAQ:DRRX) Stock Passes Above 200 Day Moving Average of $4.93June 10, 2023 | MarketBeat Internal (Ad)Save $200 on MarketBeat All AccessMarketBeat All Access is the premier all-in-one stock research solution that helps you identify the best stocks, monitor your portfolio, and keep track of the market. You get our top stock picks, best-in-class research tools, real-time alerts, proprietary research reports and much more. Claim your $200 account credit and free 30-day trial subscription today.May 18, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Durect (DRRX), Pfizer (PFE) and BioVie (BIVI)May 17, 2023 | msn.comCantor Fitzgerald Reiterates Durect (DRRX) Overweight RecommendationMay 17, 2023 | markets.businessinsider.comAnalyst Ratings for DurectMay 17, 2023 | marketwatch.com8-K: DURECT CORPMay 14, 2023 | americanbankingnews.comAnalysts Set Expectations for DURECT Co.'s FY2023 Earnings (NASDAQ:DRRX)June 10, 2023 | Behind the Markets (Ad)66,000% upside on tiny biotech?The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.May 12, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Durect (DRRX), MacroGenics (MGNX) and Precision BioSciences (DTIL)May 12, 2023 | americanbankingnews.comFY2027 Earnings Estimate for DURECT Co. (NASDAQ:DRRX) Issued By HC WainwrightMay 11, 2023 | finance.yahoo.comWall Street Analysts Think Durect (DRRX) Could Surge 594.98%: Read This Before Placing a BetMay 10, 2023 | washingtonpost.comDurect: Q1 Earnings SnapshotMay 8, 2023 | finance.yahoo.comDURECT Corporation Reports First Quarter 2023 Financial Results and Business UpdateMay 6, 2023 | americanbankingnews.comFinancial Comparison: Prothena (NASDAQ:PRTA) & DURECT (NASDAQ:DRRX)May 1, 2023 | finance.yahoo.comDURECT Corporation to Announce First Quarter 2023 Financial Results and Provide Business Update on May 8April 27, 2023 | finance.yahoo.comDURECT Corporation to Host KOL Event on Alcohol-Associated HepatitisApril 25, 2023 | finance.yahoo.comDURECT Corporation to Participate in Fireside Chat at the H.C. Wainwright BioConnect Investor ConferenceApril 25, 2023 | uk.finance.yahoo.comDURECT Corporation (DRRX) stock historical prices & data – Yahoo FinanceApril 14, 2023 | americanbankingnews.comDURECT's (DRRX) "Buy" Rating Reaffirmed at HC WainwrightApril 13, 2023 | markets.businessinsider.comH.C. Wainwright Reaffirms Their Buy Rating on Durect (DRRX)April 13, 2023 | msn.comHC Wainwright & Co. Reiterates DURECT (DRRX) Buy RecommendationApril 10, 2023 | finance.yahoo.comDURECT Announces Peer-Reviewed Article Accepted for Publication with Additional Data from Previously Completed Phase 2a Study of Larsucosterol in Alcohol-Associated HepatitisMarch 11, 2023 | finance.yahoo.comDURECT Corporation (NASDAQ:DRRX) Q4 2022 Earnings Call TranscriptMarch 9, 2023 | finance.yahoo.comDURECT Corporation Fireside Chat at the Oppenheimer 33rd Annual Healthcare ConferenceMarch 7, 2023 | finance.yahoo.comDURECT Corporation Reports Fourth Quarter and Full Year 2022 Financial Results and AHFIRM Trial UpdateJanuary 15, 2023 | fool.comDurect (NASDAQ: DRRX)See More Headlines DRRX Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart DRRX Company Calendar Last Earnings11/01/2021Today6/10/2023Next Earnings (Estimated)8/03/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:DRRX CUSIPN/A CIK1082038 Webwww.durect.com Phone(408) 777-1417Fax408-777-3577Employees79Year FoundedN/APrice Target and Rating Average Stock Price Forecast$36.25 High Stock Price Forecast$44.00 Low Stock Price Forecast$32.00 Forecasted Upside/Downside+542.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($1.58) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-35,330,000.00 Net Margins-187.82% Pretax Margin-187.82% Return on Equity-130.41% Return on Assets-56.80% Debt Debt-to-Equity RatioN/A Current Ratio1.20 Quick Ratio1.15 Sales & Book Value Annual Sales$19.28 million Price / Sales7.16 Cash FlowN/A Price / Cash FlowN/A Book Value$1.10 per share Price / Book5.13Miscellaneous Outstanding Shares24,490,000Free Float23,388,000Market Cap$138.12 million OptionableOptionable Beta1.59 Key ExecutivesJames E. BrownPresident, Chief Executive Officer & DirectorJudy R. JoiceSenior VP-Operations & Corporate Quality AssuranceTimothy M. PappChief Financial Officer & SecretaryWei Qi LinExecutive Vice President-Research & DevelopmentDavid J. EllisVice President-Clinical DevelopmentKey CompetitorsOrganigramNASDAQ:OGIChimerixNASDAQ:CMRXLumiraDxNASDAQ:LMDXESSA PharmaNASDAQ:EPIXHeron TherapeuticsNASDAQ:HRTXView All CompetitorsInsiders & InstitutionsPrelude Capital Management LLCBought 12,542 shares on 6/1/2023Ownership: 0.051%Armistice Capital LLCBought 610,000 shares on 5/16/2023Ownership: 2.491%Geode Capital Management LLCBought 8,710 shares on 5/16/2023Ownership: 0.881%Susquehanna International Group LLPBought 60,600 shares on 5/16/2023Ownership: 0.000%Ironwood Investment Management LLCBought 3,650 shares on 5/15/2023Ownership: 0.355%View All Insider TransactionsView All Institutional Transactions DRRX Stock - Frequently Asked Questions Should I buy or sell DURECT stock right now? 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for DURECT in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" DRRX shares. View DRRX analyst ratings or view top-rated stocks. What is DURECT's stock price forecast for 2023? 2 equities research analysts have issued 1 year price targets for DURECT's stock. Their DRRX share price forecasts range from $32.00 to $44.00. On average, they predict the company's share price to reach $36.25 in the next twelve months. This suggests a possible upside of 542.7% from the stock's current price. View analysts price targets for DRRX or view top-rated stocks among Wall Street analysts. How have DRRX shares performed in 2023? DURECT's stock was trading at $3.46 at the start of the year. Since then, DRRX shares have increased by 63.0% and is now trading at $5.64. View the best growth stocks for 2023 here. When is DURECT's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023. View our DRRX earnings forecast. How were DURECT's earnings last quarter? DURECT Co. (NASDAQ:DRRX) issued its earnings results on Monday, November, 1st. The specialty pharmaceutical company reported ($0.40) earnings per share for the quarter, topping the consensus estimate of ($0.50) by $0.10. The specialty pharmaceutical company earned $2.17 million during the quarter, compared to analysts' expectations of $2.18 million. DURECT had a negative trailing twelve-month return on equity of 130.41% and a negative net margin of 187.82%. During the same period in the prior year, the firm posted ($0.50) EPS. When did DURECT's stock split? DURECT's stock reverse split on the morning of Tuesday, December 6th 2022. The 1-10 reverse split was announced on Tuesday, December 6th 2022. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, December 6th 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. What other stocks do shareholders of DURECT own? Based on aggregate information from My MarketBeat watchlists, some companies that other DURECT investors own include Geron (GERN), Catalyst Pharmaceuticals (CPRX), VBI Vaccines (VBIV), MannKind (MNKD), Novavax (NVAX), Cassava Sciences (SAVA), Amarin (AMRN), Matinas BioPharma (MTNB), Inovio Pharmaceuticals (INO) and Verastem (VSTM). What is DURECT's stock symbol? DURECT trades on the NASDAQ under the ticker symbol "DRRX." Who are DURECT's major shareholders? DURECT's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Ingalls & Snyder LLC (4.96%), Armistice Capital LLC (2.49%), CM Management LLC (1.63%), Beirne Wealth Consulting Services LLC (1.16%), Renaissance Technologies LLC (1.12%) and Geode Capital Management LLC (0.88%). Insiders that own company stock include Gail J Maderis, Gail M Farfel, Judith J Robertson, Judy R Joice, Lp Bleichroeder, Mohammad Azab and Simon X Benito. View institutional ownership trends. How do I buy shares of DURECT? Shares of DRRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is DURECT's stock price today? One share of DRRX stock can currently be purchased for approximately $5.64. How much money does DURECT make? DURECT (NASDAQ:DRRX) has a market capitalization of $138.12 million and generates $19.28 million in revenue each year. The specialty pharmaceutical company earns $-35,330,000.00 in net income (profit) each year or ($1.58) on an earnings per share basis. How can I contact DURECT? DURECT's mailing address is 10260 BUBB RD, CUPERTINO CA, 95014. The official website for the company is www.durect.com. The specialty pharmaceutical company can be reached via phone at (408) 777-1417, via email at mike.arenberg@durect.com, or via fax at 408-777-3577. This page (NASDAQ:DRRX) was last updated on 6/10/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding DURECT Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.